Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353654 | 0.87 | LMNA (0.55) | SMN1; SMN2PLA2G2AMAPK1RAB9AKMT2A | |
| SCHEMBL5353454 | 0.84 | KMT2A (0.52) | SMN1; SMN2RXFP1MAPK1RAB9AKMT2A | |
| SCHEMBL5355725 | 0.81 | PDE4A (0.42) | SMN1; SMN2RAB9ACNR2ALDH1A1 | |
| SCHEMBL5361674 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2RXFP1PLA2G2AESR1MAPT | |
| SCHEMBL5364349 | 0.79 | TOP1 (0.47) | RXFP1MAPK1MAPTLMNAALDH1A1 | |
| SCHEMBL5355775 | 0.78 | THRB (0.45) | RXFP1MAPK1MAPTLMNAALDH1A1 | |
| SCHEMBL5367673 | 0.78 | THRB (0.45) | RXFP1MAPK1MAPTLMNAALDH1A1 | |
| SCHEMBL5357552 | 0.77 | PIK3CG (0.44) | SMN1; SMN2RXFP1MAPK1KMT2AMAPT | |
| SCHEMBL5357868 | 0.77 | MAPK1 (0.52) | SMN1; SMN2MAPK1RAB9AKMT2ATDP1 | |
| SCHEMBL5461262 | 0.73 | AKR1B1 (0.38) | RXFP1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | SMN1; SMN2 2454/4885RXFP1 4526/4885PLA2G2A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.